

Rajat Bannerji

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2763851/publications.pdf>

Version: 2024-02-01

9
papers

287
citations

1306789

7
h-index

1473754

9
g-index

9
all docs

9
docs citations

9
times ranked

373
citing authors

#	ARTICLE	IF	CITATIONS
1	Odronextamab, a human CD20 $\tilde{\text{A}}$ —CD3 bispecific antibody in patients with CD20-positive B-cell malignancies (ELM-1): results from the relapsed or refractory non-Hodgkin lymphoma cohort in a single-arm, multicentre, phase 1 trial. <i>Lancet Haematology</i> , 2022, 9, e327-e339.	2.2	98
2	Clinical and laboratory studies of the novel cyclin-dependent kinase inhibitor dinaciclib (SCH 727965) in acute leukemias. <i>Cancer Chemotherapy and Pharmacology</i> , 2013, 72, 897-908.	1.1	73
3	Clinical Activity of REGN1979, a Bispecific Human, Anti-CD20 x Anti-CD3 Antibody, in Patients with Relapsed/Refractory (R/R) B-Cell Non-Hodgkin Lymphoma (B-NHL). <i>Blood</i> , 2019, 134, 762-762.	0.6	50
4	Baseline Biomarkers of T-Cell Function Correlate with Clinical Responses to Odronextamab (REGN1979), and Loss of CD20 Target Antigen Expression Identified As a Mechanism of Treatment Resistance. <i>Blood</i> , 2020, 136, 10-11.	0.6	20
5	Pembrolizumab plus dinaciclib in patients with hematologic malignancies: the phase 1b KEYNOTE-155 study. <i>Blood Advances</i> , 2022, 6, 1232-1242.	2.5	14
6	Dinaciclib (SCH727965) Is a Novel Cyclin Dependent Kinase Inhibitor That Promotes Selective Apoptosis In CLL Cells and Abrogates the Protective Effects of Microenvironment Cytokines. <i>Blood</i> , 2010, 116, 971-971.	0.6	13
7	Immunotherapies Old and New: Hematopoietic Stem Cell Transplant, Chimeric Antigen Receptor T Cells, and Bispecific Antibodies for the Treatment of Relapsed/Refractory Diffuse Large B Cell Lymphoma. <i>Current Hematologic Malignancy Reports</i> , 2021, 16, 72-81.	1.2	7
8	Impact of Insurance Status on Survival Outcomes in Adults With Acute Lymphoblastic Leukemia (ALL): A Single-center Experience. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2020, 20, e890-e896.	0.2	6
9	Early Evidence of Anti-Lymphoma Activity of the Cyclin Dependent Kinase Inhibitor Dinaciclib (SCH) Tj ETQq1 1 0.784314 rgBT /Overl 2010, 116, 3966-3966.	0.6	6